Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free QUCY Stock Alerts

Mainz Biomed (QUCY) Financials

$1.16 -0.03 (-2.10%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Mainz Biomed

Annual Income Statements for Mainz Biomed

This table shows Mainz Biomed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.92 -0.59 -11 -26 -27 -22 -16
Consolidated Net Income / (Loss)		 -0.92 -0.59 -12 -26 -26 -22 -16
Net Income / (Loss) Continuing Operations		 -0.92 -0.59 -12 -26 -26 -22 -16
Total Pre-Tax Income 		-0.96 -0.59 -12 -26 -26 -22 -16
Total Operating Income		 -0.92 -0.51 -9.72 -26 -27 -19 -16
Total Gross Profit		 -0.06 0.12 0.18 0.18 0.51 0.57 0.39
Total Revenue		 0.28 0.38 0.58 0.53 0.90 0.94 1.07
Operating Revenue		 0.28 0.38 0.58 0.53 0.90 0.94 1.07
Total Cost of Revenue		 0.34 0.37 0.40 0.35 0.39 0.32 0.15
Operating Cost of Revenue		 0.34 0.37 0.40 0.35 0.39 0.32 0.15
Total Operating Expenses		 0.71 0.52 12 27 27 19 17
Selling, General & Admin Expense		 0.43 0.37 8.46 15 11 6.65 5.11
Marketing Expense		 - - 0.96 6.40 6.16 6.58 3.82
Research & Development Expense		 0.25 0.09 0.48 5.02 9.59 5.84 4.96
Impairment Charge		 - - - - - 0.00 2.64
Restructuring Charge		 - - - - - 0.28 0.00
Other Special Charges / (Income)		 - - - - - -0.05 0.16
Total Other Income / (Expense), net		 -0.14 -0.08 0.05 0.10 -0.07 -2.92 -0.44
Interest Expense		 0.16 0.18 0.34 0.24 0.52 0.95 0.37
Other Income / (Expense), net		 0.02 0.10 0.39 0.41 0.60 -1.97 -0.07
Income Tax Expense		 0.00 - 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.17) - ($1.62) ($74.55) ($64.76) ($21.91) ($2.70)
Weighted Average Basic Shares Outstanding		 5.61M 5.61M 7.21M 353.94K 406.06K 985.72K 6.00M
Diluted Earnings per Share		 ($0.17) - - ($74.55) ($64.76) ($21.91) ($2.70)
Weighted Average Diluted Shares Outstanding		 5.61M 5.61M 7.21M 14.16M 16.24M 985.72K 6.00M

Quarterly Income Statements for Mainz Biomed

This table shows Mainz Biomed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.00 -5.08
Consolidated Net Income / (Loss)		 -5.00 -5.08
Net Income / (Loss) Continuing Operations		 -2.77 -2.49
Total Pre-Tax Income 		-2.77 -2.49
Total Operating Income		 -2.75 -2.46
Total Gross Profit		 0.00 0.00
Total Revenue		 0.00 0.00
Operating Revenue		 0.00 0.00
Total Cost of Revenue		 0.00 0.00
Total Operating Expenses		 2.75 2.46
Selling, General & Admin Expense		 1.50 2.12
Marketing Expense		 1.16 0.28
Research & Development Expense		 0.09 0.06
Total Other Income / (Expense), net		 -0.02 -0.02
Interest Expense		 0.03 0.02
Other Income / (Expense), net		 0.01 -0.01
Income Tax Expense		 0.00 0.00
Net Income / (Loss) Discontinued Operations		 -2.24 -2.60
Basic Earnings per Share		 ($1.46) ($0.43)
Weighted Average Basic Shares Outstanding		 3.43M 11.80M
Diluted Earnings per Share		 ($1.46) ($0.43)
Weighted Average Diluted Shares Outstanding		 3.43M 11.80M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.66M

Annual Cash Flow Statements for Mainz Biomed

This table details how cash moves in and out of Mainz Biomed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.02 0.53 38 45 27 -0.84 -4.92
Net Cash From Operating Activities		 0.04 0.55 38 46 29 -17 -11
Net Cash From Continuing Operating Activities		 0.04 0.55 38 46 29 -17 -11
Net Income / (Loss) Continuing Operations		 -0.96 0.59 12 26 26 -22 -16
Consolidated Net Income / (Loss)		 -0.96 0.59 12 26 26 -22 -16
Depreciation Expense		 0.05 0.06 0.07 0.38 0.87 0.70 0.62
Non-Cash Adjustments To Reconcile Net Income		 0.51 0.40 17 8.92 11 3.65 6.25
Changes in Operating Assets and Liabilities, net		 0.43 -0.49 9.28 9.91 -8.53 -0.07 -1.31
Net Cash From Investing Activities		 0.00 -0.01 -0.02 -0.66 -1.20 -0.20 -1.03
Net Cash From Continuing Investing Activities		 0.00 -0.01 -0.02 -0.66 -1.20 -0.05 -1.03
Purchase of Property, Plant & Equipment		 0.00 -0.01 -0.02 -0.66 -1.20 -0.10 -0.00
Acquisitions		 - - - - - 0.00 -0.70
Sale of Property, Plant & Equipment		 - - - 0.00 0.00 0.02 0.02
Sale and/or Maturity of Investments		 - - - - - 0.03 0.00
Other Investing Activities, net		 - - - - - - -0.35
Net Cash From Financing Activities		 -0.03 -0.01 -0.05 0.00 -1.10 17 6.76
Net Cash From Continuing Financing Activities		 -0.03 -0.01 -0.05 0.00 -1.10 17 6.76
Repayment of Debt		 -0.03 -0.04 -0.05 0.00 -1.10 -1.28 -1.24
Issuance of Debt		 0.00 0.03 0.00 - - 4.31 0.00
Issuance of Common Equity		 - - - - - 14 8.25
Other Financing Activities, net		 - - - - - - -0.24
Cash Income Taxes Paid		 - - - 0.00 0.00 0.15 0.18

Quarterly Cash Flow Statements for Mainz Biomed

This table details how cash moves in and out of Mainz Biomed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.40 3.86
Net Cash From Operating Activities		 -3.94 -2.71
Net Cash From Continuing Operating Activities		 -3.94 -3.81
Net Income / (Loss) Continuing Operations		 -5.00 -5.08
Consolidated Net Income / (Loss)		 -5.00 -5.08
Depreciation Expense		 0.16 0.06
Non-Cash Adjustments To Reconcile Net Income		 1.31 0.46
Changes in Operating Assets and Liabilities, net		 -0.41 0.75
Net Cash From Investing Activities		 -0.20 -0.65
Net Cash From Continuing Investing Activities		 0.00 -0.30
Purchase of Property, Plant & Equipment		 -0.00 -0.00
Acquisitions		 0.00 -0.30
Net Cash From Financing Activities		 -0.36 7.27
Net Cash From Continuing Financing Activities		 -0.36 8.00
Repayment of Debt		 -0.36 -0.08
Issuance of Debt		 0.00 2.09
Issuance of Preferred Equity		 0.00 6.00
Issuance of Common Equity		 0.00 0.00
Effect of Exchange Rate Changes		 0.10 -0.04
Cash Income Taxes Paid		 0.03 0.01

Annual Balance Sheets for Mainz Biomed

This table presents Mainz Biomed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.67 10 20 15 14 5.33
Total Current Assets		 0.19 9.61 18 8.98 8.02 4.21
Cash & Equivalents		 0.12 8.73 17 7.07 6.24 0.70
Prepaid Expenses		 0.02 0.77 0.99 1.20 1.36 0.47
Other Current Assets		 - - - - - 3.05
Plant, Property, & Equipment, net		 0.03 0.04 0.66 1.70 1.37 0.00
Total Noncurrent Assets		 0.46 0.39 1.20 4.73 4.12 1.11
Intangible Assets		 - 0.00 0.00 3.39 3.02 1.11
Total Liabilities & Shareholders' Equity		 -1.37 10 20 15 14 5.33
Total Liabilities		 3.41 3.68 6.14 12 7.50 4.69
Total Current Liabilities		 0.44 1.35 4.24 9.24 6.18 4.69
Short-Term Debt		 - - - - 2.29 0.18
Accounts Payable		 0.40 0.87 2.72 3.18 2.92 0.17
Other Current Liabilities		 - 0.06 0.29 0.59 1.34 0.50
Other Current Nonoperating Liabilities		 - - - - - 3.83
Total Noncurrent Liabilities		 3.68 0.58 1.20 6.21 0.95 0.00
Total Equity & Noncontrolling Interests		 -5.48 6.36 14 3.25 6.00 0.64
Total Preferred & Common Equity		 -2.74 6.36 14 3.25 6.00 0.64
Preferred Stock		 - - - 52 - 0.00
Total Common Equity		 -2.74 6.36 14 -48 6.00 0.64
Common Stock		 0.06 0.14 0.16 0.24 95 106
Retained Earnings		 -4.95 -17 -43 -69 -89 -105
Accumulated Other Comprehensive Income / (Loss)		 -0.20 0.00 0.05 -0.45 -0.55 -0.62

Quarterly Balance Sheets for Mainz Biomed

This table presents Mainz Biomed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2026
Period end date 3/31/2026
Total Assets		 7.72
Total Current Assets		 6.60
Cash & Equivalents		 4.45
Prepaid Expenses		 0.27
Other Current Assets		 1.89
Plant, Property, & Equipment, net		 0.00
Total Noncurrent Assets		 1.11
Intangible Assets		 1.11
Total Liabilities & Shareholders' Equity		 7.72
Total Liabilities		 3.13
Total Current Liabilities		 3.13
Short-Term Debt		 0.13
Accounts Payable		 0.72
Other Current Liabilities		 0.20
Other Current Nonoperating Liabilities		 2.09
Total Noncurrent Liabilities		 0.00
Total Equity & Noncontrolling Interests		 4.59
Total Preferred & Common Equity		 4.59
Preferred Stock		 0.04
Total Common Equity		 4.55
Common Stock		 115
Retained Earnings		 -110
Accumulated Other Comprehensive Income / (Loss)		 -0.65

Annual Metrics And Ratios for Mainz Biomed

This table displays calculated financial ratios and metrics derived from Mainz Biomed's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 14,629,457.00 21,165,482.00 21,165,482.00 21,165,482.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 365,736.00 529,137.00 529,137.00 529,137.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -72.01 -50.65 -40.82 -30.64
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 36.17% 50.67% -8.22% 69.00% 4.98% 13.88%
EBITDA Growth		 0.00% 58.97% -2,545.95% -176.99% 1.86% 20.37% 22.23%
EBIT Growth		 0.00% 54.70% -2,173.25% -178.99% -0.04% 20.34% 21.88%
NOPAT Growth		 0.00% 44.52% -1,801.32% -171.93% -0.76% 29.54% 14.03%
Net Income Growth		 0.00% 35.98% -1,891.86% -125.72% 0.35% 17.86% 24.95%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.35% 66.17% 87.68%
Operating Cash Flow Growth		 0.00% 1,244.90% 6,809.52% 19.23% -35.50% -158.93% 36.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -477.94% -85.71% -32.23% 48.44% -10.53%
Invested Capital Growth		 0.00% 0.00% 91.84% -431.45% 363.52% -36.95% 92.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 -21.77% 32.12% 30.77% 34.38% 56.91% 61.15% 36.41%
EBITDA Margin		 -303.17% -91.34% -1,604.10% -4,841.28% -2,811.55% -2,132.75% -1,456.38%
Operating Margin		 -327.62% -133.48% -1,684.36% -4,990.60% -2,975.47% -1,996.98% -1,507.51%
EBIT Margin		 -322.02% -107.12% -1,616.22% -4,912.96% -2,908.31% -2,206.85% -1,513.90%
Profit (Net Income) Margin		 -325.77% -153.16% -2,024.79% -4,979.90% -2,936.50% -2,297.55% -1,514.20%
Tax Burden Percent		 95.78% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 105.62% 142.98% 125.28% 101.36% 100.97% 104.11% 100.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -1,843.63% -494.35% -376.09%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -1,743.85% -63.99% 1,179.71%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 1,540.43% 27.20% -112.23%
Return on Equity (ROE)		 0.00% 10.70% -2,662.76% -257.98% -303.20% -467.15% -488.32%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -709.95% -449.02% -439.21%
Operating Return on Assets (OROA)		 0.00% -60.97% -174.19% -171.94% -146.11% -143.52% -172.16%
Return on Assets (ROA)		 0.00% -87.17% -218.22% -174.28% -147.52% -149.42% -172.19%
Return on Common Equity (ROCE)		 0.00% 5.35% -10,976.79% -257.98% 597.17% 2,134.94% -488.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 21.41% -183.77% -187.20% -809.29% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.65 -0.36 -6.81 -19 -19 -13 -11
NOPAT Margin		 -229.34% -93.43% -1,179.05% -3,493.42% -2,082.83% -1,397.89% -1,055.25%
Net Nonoperating Expense Percent (NNEP)		 0.00% 17.40% -246.41% -71.84% -99.78% -430.36% -1,555.80%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -130.92% -228.78% -158.49% -1,368.87%
Cost of Revenue to Revenue		 121.77% 96.68% 69.23% 65.62% 43.09% 33.94% 13.76%
SG&A Expenses to Revenue		 152.41% 97.75% 1,464.91% 2,870.46% 1,273.67% 707.45% 477.08%
R&D to Revenue		 88.96% 22.89% 83.47% 947.27% 1,070.98% 621.12% 463.35%
Operating Expenses to Revenue		 253.85% 136.79% 2,055.56% 5,014.27% 2,993.41% 2,053.16% 1,559.16%
Earnings before Interest and Taxes (EBIT)		 -0.91 -0.41 -9.33 -26 -26 -21 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.85 -0.35 -9.26 -26 -25 -20 -16
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.27 6.05 0.00 0.38 0.92
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.27 6.05 0.00 0.77 0.00
Price to Revenue (P/Rev)		 35.54 26.10 35.99 160.93 18.95 2.43 0.55
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 20.34 0.00 0.02
Enterprise Value to Revenue (EV/Rev)		 0.00 20.49 21.21 128.66 74.05 0.00 0.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 14.18 0.32 1.50 2.25 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 3.15 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 -0.13 0.03 0.00 1.51 0.38 0.29
Long-Term Debt to Equity		 0.00 -0.13 0.03 0.00 1.51 0.00 0.00
Financial Leverage		 0.00 -0.48 -4.51 -1.07 -0.88 -0.43 -0.10
Leverage Ratio		 0.00 -0.12 12.20 1.48 2.06 3.13 2.84
Compound Leverage Factor		 0.00 -0.18 15.29 1.50 2.08 3.25 2.84
Debt to Total Capital		 0.00% -14.97% 2.95% 0.30% 60.14% 27.66% 22.26%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 27.66% 22.26%
Long-Term Debt to Total Capital		 0.00% -14.97% 2.95% 0.30% 60.14% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 631.80% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 57.48% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 57.48% 97.05% 99.70% -591.94% 72.34% 77.74%
Debt to EBITDA		 0.00 -2.04 -0.02 0.00 -0.19 -0.11 -0.01
Net Debt to EBITDA		 0.00 -1.69 0.92 0.67 0.09 0.20 0.03
Long-Term Debt to EBITDA		 0.00 -2.04 -0.02 0.00 -0.19 0.00 0.00
Debt to NOPAT		 0.00 -1.99 -0.03 0.00 -0.26 -0.17 -0.02
Net Debt to NOPAT		 0.00 -1.65 1.25 0.92 0.12 0.30 0.05
Long-Term Debt to NOPAT		 0.00 -1.99 -0.03 0.00 -0.26 0.00 0.00
Altman Z-Score		 0.00 -10.43 -0.95 1.97 -11.00 -13.85 -37.44
Noncontrolling Interest Sharing Ratio		 0.00% 50.00% -312.23% 0.00% 296.95% 557.01% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 0.43 7.11 4.33 0.97 1.30 0.90
Quick Ratio		 0.00 0.38 6.54 4.06 0.78 1.02 0.15
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 2.49 -9.43 -18 -23 -12 -13
Operating Cash Flow to CapEx		 0.00% 5,714.00% 228,897.67% 6,923.65% 2,452.94% -21,236.31% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 14.14 -27.79 -72.33 -44.31 -12.62 -35.33
Operating Cash Flow to Interest Expense		 0.26 3.14 112.74 188.38 56.29 -18.33 -29.40
Operating Cash Flow Less CapEx to Interest Expense		 0.26 3.08 112.69 185.66 54.00 -18.41 -29.36
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.57 0.11 0.04 0.05 0.07 0.11
Accounts Receivable Turnover		 0.00 8.66 7.40 5.93 11.16 13.02 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.65 0.00
Fixed Asset Turnover		 0.00 12.63 16.93 1.51 0.76 0.61 0.00
Accounts Payable Turnover		 0.00 0.92 0.63 0.19 0.13 0.10 0.10
Days Sales Outstanding (DSO)		 0.00 42.14 49.34 61.59 32.72 28.03 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 564.19 0.00
Days Payable Outstanding (DPO)		 0.00 396.03 580.52 1,882.49 2,791.59 3,492.69 3,834.70
Cash Conversion Cycle (CCC)		 0.00 -353.89 -531.19 -1,820.90 -2,758.87 -2,900.47 -3,834.70
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -2.85 -0.23 -1.24 3.26 2.06 3.95
Invested Capital Turnover		 0.00 -0.27 -0.37 -0.72 0.89 0.35 0.36
Increase / (Decrease) in Invested Capital		 0.00 -2.85 2.62 -1.00 4.50 -1.20 1.90
Enterprise Value (EV)		 0.00 7.85 12 68 66 -1.66 0.07
Market Capitalization		 10 10 21 85 17 2.29 0.59
Book Value per Share		 $0.00 ($0.49) $0.88 $1.17 ($3.30) $0.28 $0.11
Tangible Book Value per Share		 $0.00 ($0.49) $0.88 $1.17 ($3.53) $0.14 ($0.08)
Total Capital		 0.00 -4.77 6.55 14 8.15 8.29 0.83
Total Debt		 0.00 0.71 0.19 0.04 4.90 2.29 0.18
Total Long-Term Debt		 0.00 0.71 0.19 0.04 4.90 0.00 0.00
Net Debt		 0.00 0.59 -8.53 -17 -2.17 -3.94 -0.52
Capital Expenditures (CapEx)		 0.00 0.01 0.02 0.66 1.20 0.08 -0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.37 -0.47 -3.01 -7.33 -2.10 -0.99
Debt-free Net Working Capital (DFNWC)		 0.00 -0.25 8.26 14 -0.26 4.13 -0.29
Net Working Capital (NWC)		 0.00 -0.25 8.26 14 -0.26 1.84 -0.47
Net Nonoperating Expense (NNE)		 0.27 0.23 4.88 7.88 7.64 8.46 4.91
Net Nonoperating Obligations (NNO)		 0.00 2.63 -6.59 -15 0.01 -3.94 3.31
Total Depreciation and Amortization (D&A)		 0.05 0.06 0.07 0.38 0.87 0.70 0.62
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -96.95% -81.42% -567.31% -818.33% -223.76% -92.45%
Debt-free Net Working Capital to Revenue		 0.00% -64.96% 1,430.24% 2,667.74% -28.70% 439.56% -26.91%
Net Working Capital to Revenue		 0.00% -64.96% 1,430.24% 2,667.74% -28.70% 195.57% -44.07%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.62) $0.00 $0.00 ($22.36) ($2.70)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 7.21M 365.74K 529.14K 968.23K 6.00M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.62) $0.00 $0.00 ($22.36) ($2.70)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 7.21M 365.74K 529.14K 2.32M 6.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.62) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 7.21M 353.94K 406.06K 2.32M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.65 -0.36 -6.81 -19 -19 -13 -9.33
Normalized NOPAT Margin		 -229.34% -93.43% -1,179.05% -3,493.42% -2,082.83% -1,380.74% -871.95%
Pre Tax Income Margin		 -340.11% -153.16% -2,024.79% -4,979.90% -2,936.50% -2,297.55% -1,514.20%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -5.78 -2.33 -27.51 -107.56 -49.85 -21.94 -43.40
NOPAT to Interest Expense		 -4.11 -2.03 -20.07 -76.48 -35.70 -13.90 -30.25
EBIT Less CapEx to Interest Expense		 -5.78 -2.38 -27.56 -110.28 -52.15 -22.03 -43.35
NOPAT Less CapEx to Interest Expense		 -4.11 -2.08 -20.12 -79.21 -38.00 -13.98 -30.21
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mainz Biomed

This table displays calculated financial ratios and metrics derived from Mainz Biomed's official financial filings.

Metric Q1 2025 Q1 2026
Period end date 3/31/2025 3/31/2026
DEI Shares Outstanding		 21,165,482.00 21,165,482.00
DEI Adjusted Shares Outstanding		 529,137.00 529,137.00
DEI Earnings Per Adjusted Shares Outstanding		 -9.45 -9.60
Growth Metrics		 - -
Revenue Growth		 0.00% 0.00%
EBITDA Growth		 0.00% 6.35%
EBIT Growth		 0.00% 9.74%
NOPAT Growth		 0.00% 10.29%
Net Income Growth		 0.00% -1.58%
EPS Growth		 0.00% 70.55%
Operating Cash Flow Growth		 0.00% 31.31%
Free Cash Flow Firm Growth		 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00%
Profitability Metrics		 - -
Gross Margin		 0.00% 0.00%
EBITDA Margin		 0.00% 0.00%
Operating Margin		 0.00% 0.00%
EBIT Margin		 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00%
Tax Burden Percent		 180.78% 204.46%
Interest Burden Percent		 101.12% 100.61%
Effective Tax Rate		 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.92 -1.72
NOPAT Margin		 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -300.50%
Return On Investment Capital (ROIC_SIMPLE)		 - -36.56%
Cost of Revenue to Revenue		 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00%
R&D to Revenue		 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.74 -2.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.58 -2.41
Valuation Ratios		 - -
Price to Book Value (P/BV)		 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00
Dividend Yield		 0.00% 0.00%
Earnings Yield		 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00
Leverage & Solvency		 - -
Debt to Equity		 0.00 0.03
Long-Term Debt to Equity		 0.00 0.00
Financial Leverage		 0.00 -0.49
Leverage Ratio		 0.00 1.68
Compound Leverage Factor		 0.00 1.69
Debt to Total Capital		 0.00% 2.69%
Short-Term Debt to Total Capital		 0.00% 2.69%
Long-Term Debt to Total Capital		 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.75%
Noncontrolling Interests to Total Capital		 0.00% 0.00%
Common Equity to Total Capital		 0.00% 96.56%
Debt to EBITDA		 0.00 -0.01
Net Debt to EBITDA		 0.00 0.28
Long-Term Debt to EBITDA		 0.00 0.00
Debt to NOPAT		 0.00 -0.01
Net Debt to NOPAT		 0.00 0.39
Long-Term Debt to NOPAT		 0.00 0.00
Altman Z-Score		 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00%
Liquidity Ratios		 - -
Current Ratio		 0.00 2.11
Quick Ratio		 0.00 1.42
Cash Flow Metrics		 - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.08
Operating Cash Flow to CapEx		 -324,183.63% -411,549.09%
Free Cash Flow to Firm to Interest Expense		 0.00 -268.77
Operating Cash Flow to Interest Expense		 -129.10 -178.45
Operating Cash Flow Less CapEx to Interest Expense		 -129.14 -178.49
Efficiency Ratios		 - -
Asset Turnover		 0.00 0.14
Accounts Receivable Turnover		 0.00 0.00
Inventory Turnover		 0.00 0.00
Fixed Asset Turnover		 0.00 0.00
Accounts Payable Turnover		 0.00 0.21
Days Sales Outstanding (DSO)		 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 1,773.86
Cash Conversion Cycle (CCC)		 0.00 -1,773.86
Capital & Investment Metrics		 - -
Invested Capital		 0.00 2.35
Invested Capital Turnover		 0.00 0.91
Increase / (Decrease) in Invested Capital		 0.00 2.35
Enterprise Value (EV)		 0.00 0.00
Market Capitalization		 1.70 0.00
Book Value per Share		 $0.00 $0.39
Tangible Book Value per Share		 $0.00 $0.29
Total Capital		 0.00 4.72
Total Debt		 0.00 0.13
Total Long-Term Debt		 0.00 0.00
Net Debt		 0.00 -4.32
Capital Expenditures (CapEx)		 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.85
Debt-free Net Working Capital (DFNWC)		 0.00 3.60
Net Working Capital (NWC)		 0.00 3.48
Net Nonoperating Expense (NNE)		 3.08 3.36
Net Nonoperating Obligations (NNO)		 0.00 -2.23
Total Depreciation and Amortization (D&A)		 0.16 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -79.17%
Debt-free Net Working Capital to Revenue		 0.00% 336.51%
Net Working Capital to Revenue		 0.00% 324.67%
Earnings Adjustments		 - -
Adjusted Basic Earnings per Share		 $0.00 ($0.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 11.80M
Adjusted Diluted Earnings per Share		 $0.00 ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 11.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.92 -1.72
Normalized NOPAT Margin		 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00%
Debt Service Ratios		 - -
EBIT to Interest Expense		 -89.64 -162.80
NOPAT to Interest Expense		 -62.94 -113.62
EBIT Less CapEx to Interest Expense		 -89.68 -162.84
NOPAT Less CapEx to Interest Expense		 -62.98 -113.66
Payout Ratios		 - -
Dividend Payout Ratio		 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00%

Financials Breakdown Chart

Mainz Biomed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mainz Biomed's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Mainz Biomed's net income appears to be on an upward trend, with a most recent value of -$16.21 million in 2025, rising from -$916.69 thousand in 2019. The previous period was -$21.60 million in 2024. See Mainz Biomed's forecast for analyst expectations on what's next for the company.

Mainz Biomed's total operating income in 2025 was -$16.14 million, based on the following breakdown:
  • Total Gross Profit: $389.79 thousand
  • Total Operating Expenses: $16.69 million

Over the last 6 years, Mainz Biomed's total revenue changed from $281.39 thousand in 2019 to $1.07 million in 2025, a change of 280.5%.

Mainz Biomed's total liabilities were at $4.69 million at the end of 2025, a 37.6% decrease from 2024, and a 37.2% increase since 2020.

In the past 5 years, Mainz Biomed's cash and equivalents has ranged from $122.57 thousand in 2020 to $17.14 million in 2022, and is currently $701.60 thousand as of their latest financial filing in 2025.

Over the last 6 years, Mainz Biomed's book value per share changed from 0.00 in 2019 to 0.11 in 2025, a change of 10.7%.


Related Companies

Financial statements for NASDAQ:QUCY last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel